Osimertinib or Platinum–Pemetrexed in <i>EGFR</i> T790M–Positive Lung CancerTony Mok, Vassiliki A. Papadimitrakopoulou, Yi‐Long Wu et al.|New England Journal of Medicine|2016Cited by 3.3k
Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133)Stephen V. Liu, Leora Horn, Aaron S. Mansfield et al.|Journal of Clinical Oncology|2021Cited by 818
Artificial intelligence for predictive biomarker discovery in immuno-oncology: a systematic reviewArsela Prelaj, A.L.G. Pedrocchi, V. Miskovic et al.|Annals of Oncology|2023Cited by 286
Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage non-small-cell lung cancer (KEYNOTE-671): a randomised, double-blind, placebo-controlled, phase 3 trialJonathan Spicer, Marina Chiara Garassino, Heather A. Wakelee et al.|The Lancet|2024Cited by 233
Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLCMarcelo V. Negrão, Sandip Pravin Patel, Haniel A. Araújo et al.|Cancer Discovery|2023Cited by 181